zidovudine + lamivudine + abacavir + tenofovir disoproxil fumarate

This combination regimen consists of four nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs): zidovudine, lamivudine, abacavir, and tenofovir disoproxil fumarate. It was specifically evaluated in a Phase 2 pilot study (NCT00356616) sponsored by the Germans Trias i Pujol Hospital for the treatment of HIV-1 infected patients experiencing virological failure and harboring multiple antiretroviral resistances. The regimen utilizes the fixed-dose combination product Trizivir (containing zidovudine, lamivudine, and abacavir) supplemented with tenofovir disoproxil fumarate (Viread). All four components act by competitively inhibiting the HIV-1 reverse transcriptase enzyme and inducing viral DNA chain termination, thereby blocking viral replication. The study aimed to determine if this NRTI-only regimen could preserve immunological status (stable CD4 lymphocyte counts) in patients for whom an efficacious salvage regimen could not be designed, while potentially reducing treatment-associated toxicity.

Other names

Trizivir + TenofovirAZT + 3TC + ABC + TDFTrizivir + Viread